2008

Dr. Sunanda Singh M.D., Ph.D. leveraged his scientific experience and medical background in order to look for new and novel techniques to treat cancer and auto-immune diseases using immunologic technology.

2011

Dr. Sunanda Singh M.D., Ph.D. narrowed his focus to look at the role of STAT3 in cancer.

2012

  • Dr. Sunanda Singh M.D., Ph.D. independently conceptualized the development of novel biological therapeutics inhibitors to target STAT3, mutated KRAS, and TNF-alpha.
  • Dr. Sunanda Singh M.D., Ph.D. sets up an exploratory drug development team to determine the feasibility of the novel biological therapeutic inhibitors developed.
  • Dr. Anjali H. Singh M.D. added to exploratory drug development team as Principal Medical Advisor Consultant.           
  • Ashu Parihar added to the exploratory drug development team as Scientific Research and Development Consultant.

2013  

  • Dr. Sunanda Singh M.D., Ph.D. initiated the production of his novel biological therapeutic inhibitors to STAT3, mutated KRAS, and TNF-alpha.
  • Initiation and completion of preliminary in vitro studies of the novel biological therapeutic inhibitors to STAT3.
  • Ameeta Patel, MBA added to exploratory drug development team as Consultant for Business Development and Market Analysis.

2014

  • Independently patent filed for each novel biological therapeutic inhibitor.
  • In vitro efficacy studies initiated and completed at an independent contract research laboratory for STAT3 inhibitors (SBT-100 and SBT-101).
  • Pilot toxicology study performed on the biological therapeutic inhibitors SBT-100 and SBT-101.
  • Dr. Sunanda Singh M.D., Ph.D. incorporates Singh Biotechnology, LLC. and becomes Founder and CEO.
  • Dr. Sunanda Singh M.D., Ph.D. initiates the establishment of Singh Biotechnology, LLC. management team with the addition of Dr. Anjali H. Singh M.D. as Director of Clinical Dermatology; Ameeta Patel, MBA as Head of Business Development; Ashu Parihar as Vice President of Research. 
  • Dr. Hector J. Gomez, M.D., Ph.D. joins the management team as Chairman of Scientific Advisory Committee at Singh Biotechnology, LLC.

2015  

  • Efficacy studies in vivo of SBT-100 completed.
  • Singh Biotechnology, LLC. accepted into the Tampa Bay Technology Incubator (TBTI) at the University of South Florida.
  • Initiated and completed preliminary in vitro studies of the novel biological therapeutic inhibitors for the mutated KRAS and TNF-alpha.
  • Initiation of the first round of private investors funding for research and development at Singh Biotechnology, LLC.

2016

  • Two abstracts accepted to 2016 ASCO (American Society of Clinical Oncologists) Meeting at Chicago in June.
  • One abstract accepted to the 2016 SABCS (San Antonio Breast Cancer Symposium) in December.
  • FDA Grants Orphan Drug Status to SBT-100 for the treatment of pancreatic cancer.

What is a scientist after all? It is a curious man looking through a keyhole, the keyhole of nature, trying to know what's going on.

-Jacques Yves Cousteau